시장보고서
상품코드
1132593

미국의 RWE(Real World Evidence) 솔루션 시장 : 컴포넌트별(데이터세트 : 임상, 청구, 약국, 통합/서비스), 용도별(시장 접근, 종양학, 신경학), 최종사용자별(제약, 의료 제공자) 예측(-2029년)

U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy, Integrated), Services], Application (Market Access, Oncology, Neurology), End User (Pharma Companies, Providers) - Forecast to 2029

발행일: | 리서치사: Meticulous Market Research Pvt. Ltd. | 페이지 정보: 영문 103 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

미국의 RWE(Real World Evidence) 솔루션 시장 규모는 2022-2029년 13.1%의 CAGR로 성장하며, 2029년에는 22억 2,000만 달러에 달할 것으로 예측되고 있습니다. 시장의 성장을 지원하는 주요 요인으로는 만성질환 및 감염증의 발생률 증가, 의약품 개발의 지연과 이에 따른 개발비의 증가, 맞춤형 의료에 대한 주목의 증가, 양으로부터 가치에 기반한 의료로의 이동, 의료에서 빅데이터의 급증 등을 들 수 있습니다.

미국의 RWE(Real World Evidence) 솔루션 시장을 조사했으며, 시장의 개요, 시장 규모 및 예측, 동향, 촉진요인·억제요인, 경쟁 구도, 컴포넌트별·용도별·최종사용자별 분석 및 기업 개요 등을 정리하여 전해드립니다.

목차

제1장 서론

  • 시장의 정의
  • 시장 에코시스템
  • 통화

제2장 조사 방법

  • 조사 프로세스
  • 데이터 수집과 검증
    • 2차 조사
    • 1차 조사
  • 시장 평가
    • 시장 규모 예측
    • 시장 점유율 분석
  • 조사의 전제조건
  • 조사의 제한

제3장 주요 요약

제4장 시장 인사이트

  • 시장 개요
  • 촉진요인
    • 만성질환 및 감염증의 부담 증대
    • 맞춤형 의료에 대한 관심의 증가
    • 의약품 개발 지연과 이에 따른 개발비의 증가
    • 가치에 기반한 케어로의 이동
    • 의료에서 급속히 확대하는 빅데이터
  • 억제요인
    • 리얼월드 연구에 의지하는 것에 대한 주저
  • 기회
    • 엔드 투 엔드 RWE 서비스에 대한 관심의 증가
    • RWE에서 웨어러블 디바이스와 인공지능의 채택 증가
  • 과제
    • RWE를 개발하기 위한 표준화된 방법의 결여
  • 주요 시장 동향
    • 의약품의 개발과 상업화에서 RWE의 채택 확대
    • 합병 수의 증가
    • RWE에 기반한 환자 결과의 개선과 가치 창조
  • 미국의 RWE(Real World Evidence) 솔루션 시장에 대한 COVID-19의 영향 평가

제5장 규제 분석 : 미국의 RWE(Real World Evidence) 솔루션 시장

제6장 가격결정 모델(EMR/게놈/통합 데이터세트)

  • 서론
  • 환자 진료기록카드당 지불(수량 기반 가격결정)
  • 종량과금제(금액 기반 가격결정)
  • 연간 회비

제7장 미국의 RWE(Real World Evidence) 솔루션 시장 : 컴포넌트별

  • 서론
  • 데이터세트
    • 이종 데이터세트
    • 통합 데이터세트
  • 컨설팅·분석

제8장 미국의 RWE(Real World Evidence) 솔루션 시장 : 용도별

  • 서론
  • 시장 접근과 상환/적용 범위 결정
  • 의약품의 개발과 승인
    • 종양학
    • 신경학
    • 면역학
    • 심혈관질환
    • 기타 치료 영역
  • 의료기기의 개발과 승인
  • 시판후조사
  • 기타

제9장 미국의 RWE(Real World Evidence) 솔루션 시장 : 최종사용자별

  • 서론
  • 제약, 바이오테크놀러지, 의료기기 기업
  • 의료비 지불자
  • 의료 제공자
  • 기타

제10장 경쟁 구도

  • 서론
  • 주요 성장 전략
  • 경쟁 벤치마킹
  • 시장 점유율 분석(2020년)
    • IQVIA Holdings, Inc.
    • ICON plc
    • PPD, Inc.

제11장 기업 개요(사업 개요, 재무 개요, 솔루션 포트폴리오, 전략적 개발)

  • Anthem, Inc.
  • Clinigen Group plc.
  • Cognizant Technology Solutions Corporation
  • ICON plc
  • IQVIA HOLDINGS INC.
  • Oracle Corporation
  • PAREXEL International Corporation
  • PerkinElmer, Inc.
  • PPD, Inc.
  • SAS Institute Inc.
  • UnitedHealth Group Incorporated
  • Flatiron Health, Inc.
KSA 22.10.20

U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy), Services], Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers)- Forecast to 2029

The U.S. RWE solutions market is expected to grow at a CAGR of 13.1% from 2022 to 2029 to reach $2.22 billion by 2029

Following a thorough secondary and primary research and in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, challenges, and opportunities

Growing incidence of chronic & infectious diseases, delays in drug development and the subsequent increase in development costs, rising focus towards personalized healthcare, a shift from volume to value-based care, and rapidly growing big data in healthcare are the key factors driving steady growth in the U.S. RWE solutions market. Further, significant opportunities for existing market players and new entrants are provided by rising focus on end-to-end RWE services, and rising adoption of wearable devices and AI in RWE

Based on component, in 2022, the datasets segment is expected to command the largest share in the market. Real-world data (RWD) are derived from various sources associated with outcomes in a heterogeneous patient population in real-world settings. Datasets are present in a secondary format on which retrospective studies are conducted to generate real-world evidence. This real-world evidence provides meaningful insights into unmet needs and the clinical and economic impacts on patients and healthcare systems. It also determines the outcomes based on much larger data samples, reduces costs, and improves the efficiency of clinical trials.

Based on application, the drug development & approvals segment is expected to show the fastest growth rate in the forecast period. Factors attributing towards the growth of this segment are increasing demand for real-world data and real-world evidence to accelerate drug discovery and development, and increasing investments by biopharmaceutical companies in R&D.

In the field of drug development, quality-of-life metrics, and Patient-Reported Outcome Measures (PROMs) are now becoming common elements in clinical trials. The evidence generated from real-world data is regularly utilized to inform aspects of drug development. The role of RWE in drug development is expanding as RWE studies are significantly less costly and time-consuming than RCTs, providing easier access to long-term effectiveness data and helping overcome some of the feasibility barriers of running RCTs.

Based on end user, the pharmaceutical & medical device companies segment is expected to show the fastest growth rate in the forecast period. The growth of this segment is primarily attributed to the increasing importance of RWE studies in drug development & approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings.

The cost of developing a new drug was more than ~USD 2,600 million in 2020 compared to USD 802 million in 2003. This increase in drug development costs reflects various technical, regulatory, and economic challenges pharmaceutical R&D pipelines face.

The key companies operating in the U.S. RWE solutions market are Anthem, Inc. (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), ICON plc (Ireland), IQVIA HOLDINGS INC. (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), PPD, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health, Inc. (U.S.).

Scope of the Report

U.S. RWE Solutions Market, by Component

  • Datasets
  • Disparate Datasets
  • EMR/EHR/Clinical Data
  • Claims & Billing Data
  • Pharmacy Data
  • Product/Disease Registries Data
  • Other Disparate Datasets
  • Integrated Datasets
  • Consulting and Analytics

(Note - Other Disparate Datasets include data generated from mobile devices, wearable devices, and social media)

U.S. RWE Solutions Market, by Application

  • Market Access & Reimbursement/Coverage Decisions
  • Drug Development & Approvals
  • Oncology
  • Neurology
  • Immunology
  • Cardiovascular Diseases
  • Other Therapeutic Areas
  • Post Market Surveillance
  • Medical Device Development & Approvals
  • Clinical and Regulatory Decision-Making

(Note - Other Therapeutic Areas include infectious diseases, musculoskeletal disorders, dermatological diseases, and respiratory diseases)

U.S. RWE Solutions Market, by End User

  • Pharmaceutical, Biotechnology, and Medical Device Companies
  • Healthcare Payers
  • Healthcare Providers
  • Other End Users

(Note - Other end users include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies)

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Ecosystem
  • 1.3. Currency

2. Research Methodology

  • 2.1. Research Process
  • 2.2. Data Collection & Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research
  • 2.3. Market Assessment
    • 2.3.1. Market Size Estimation
      • 2.3.1.1. Bottom-Up Approach
      • 2.3.1.2. Top-Down Approach
      • 2.3.1.3. Growth Forecast
    • 2.3.2. Market Share Analysis
  • 2.4. Assumptions for the Study
  • 2.5. Limitations for the Study

3. Executive Summary

4. Market Insights

  • 4.1. Market Overview
  • 4.2. Drivers
    • 4.2.1. Growing Burden of Chronic and Infectious Diseases
    • 4.2.2. Rising Focus Towards Personalized Healthcare
    • 4.2.3. Delays in Drug Development and the Subsequent Increase in Development Costs
    • 4.2.4. Shift Towards Value-Based Care
    • 4.2.5. Rapidly Growing Big Data in Healthcare
  • 4.3. Restraints
    • 4.3.1. Reluctance to Rely on Real-World Studies
  • 4.4. Opportunities
    • 4.4.1. Rising Focus on End-to-End RWE Services
    • 4.4.2. Rising Adoption of Wearable Devices and Artificial Intelligence in RWE
  • 4.5. Challenges
    • 4.5.1. Lack of Standardized Methodologies to Develop RWE
  • 4.6. Key Market Trends
    • 4.6.1. Growing Adoption of RWE in Drug Development and Commercialization
    • 4.6.2. Rising Number of Consolidations
    • 4.6.3. Improved Patient Outcomes and Value Creation from Real-World Evidence
  • 4.7. Impact Assessment of COVID-19 on the U.S. RWE Solutions Market

5. Regulatory Analysis - U.S. Real-World Evidence (RWE) Solutions Market

6. Pricing Models (EMR/Genomic/Integrated Datasets)

  • 6.1. Introduction
  • 6.2. Pay Per Patient Record (Volume-Based Pricing)
  • 6.3. Pay Per Usage (Value-Based Pricing)
  • 6.4. Annual Subscription

7. U.S. Real-World Evidence Solutions Market, by Component

  • 7.1. Introduction
  • 7.2. Datasets
    • 7.2.1. Disparate Datasets
      • 7.2.1.1. EMR/EHR/Clinical Data
      • 7.2.1.2. Claims & Billing Data
      • 7.2.1.3. Pharmacy Data
      • 7.2.1.4. Product/Disease Registries Data
      • 7.2.1.5. Other Disparate Datasets
    • 7.2.2. Integrated Datasets
  • 7.3. Consulting & Analytics

8. U.S. Real-World Evidence Solutions Market, by Application

  • 8.1. Introduction
  • 8.2. Market Access & Reimbursement/Coverage Decisions
  • 8.3. Drug Development & Approvals
    • 8.3.1. Oncology
    • 8.3.2. Neurology
    • 8.3.3. Immunology
    • 8.3.4. Cardiovascular Diseases
    • 8.3.5. Other Therapeutic Areas
  • 8.4. Medical Device Development & Approvals
  • 8.5. Post-Market Surveillance
  • 8.6. Other Applications

9. U.S. Real-World Evidence Solutions Market, by End User

  • 9.1. Introduction
  • 9.2. Pharmaceutical, Biotechnology, and Medical Device Companies
  • 9.3. Healthcare Payers
  • 9.4. Healthcare Providers
  • 9.5. Other End Users

10. Competitive Landscape

  • 10.1. Introduction
  • 10.2. Key Growth Strategies
  • 10.3. Competitive Benchmarking
  • 10.4. Market Share Analysis (2020)
    • 10.4.1. IQVIA Holdings, Inc. (U.S.)
    • 10.4.2. ICON plc (Ireland)
    • 10.4.3. PPD, Inc. (U.S.)

11. Company Profiles (Business Overview, Financial Overview, Solution Portfolio, Strategic Developments)

  • 11.1. Anthem, Inc.
  • 11.2. Clinigen Group plc.
  • 11.3. Cognizant Technology Solutions Corporation
  • 11.4. ICON plc
  • 11.5. IQVIA HOLDINGS INC.
  • 11.6. Oracle Corporation
  • 11.7. PAREXEL International Corporation
  • 11.8. PerkinElmer, Inc.
  • 11.9. PPD, Inc.
  • 11.10. SAS Institute Inc.
  • 11.11. UnitedHealth Group Incorporated
  • 11.12. Flatiron Health, Inc.
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제